# The deal involves Regeneron lowering the prices of all its current and future drugs on Medicaid.

*biotech · news · 2026-04-24 · Anchorage Daily News*

## Key points

- Regeneron will lower the prices of all current and future drugs on Medicaid under this deal.
- Regeneron agreed to sell Praluent for $225 via the TrumpRx discounted drug website.
- Regeneron will invest $27 billion in U.S. research, development, and manufacturing per the new agreement.
- Regeneron's Otarmeni gene therapy for congenital hearing loss was FDA-approved and will be free to eligible U.S. patients.
- The FDA's expedited approval of Otarmeni used the controversial Commissioner's National Priority Voucher program.

**Companies:** Regeneron
**Countries:** United States

[Read the full story on Anchorage Daily News](https://www.adn.com/nation-world/2026/04/23/trump-unveils-deal-with-regeneron-to-lower-drug-prices-as-part-of-most-favored-nation-initiative/)

---

Canonical: https://newsio.io/n/4f308289-b5f4-4617-bbac-cab86d3cf6b1/the-deal-involves-regeneron-lowering-the-prices-of-all-its-current-and-future-dr
Summarized by Newsio from Anchorage Daily News. https://newsio.io/how-it-works